Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This study is non-randomized, multicenter, confirmatory study by intrathecal administration
of KP-100IT, code of HGF (Hepatocyte Growth Factor ) formulation for intrathecal injection,
in subjects with acute spinal cord injury.